Precipio
Yahoo Finance • last year
Precipio Announces Q3-2023 Shareholder Update Call
NEW HAVEN, Conn., Nov. 16, 2023 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), will be hosting its Q3-2023 corporate update call on November 20th, 2023 at 5:00 PM ET. The call will include updates... Full story
Yahoo Finance • last year
Precipio to Report $4.5M Q3-2023 Revenues, Double From Q3-2022
NEW HAVEN, Conn., Oct. 18, 2023 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc.(NASDAQ: PRPO), announces that Q3-2023 (unaudited) revenues have increased 28% to $4.5M from $3.5M in Q2-2023, and have more than doub... Full story
Yahoo Finance • last year
Precipio’s Q3 Cash Burn From Operations (unaudited) Declines 59% YoY, from $2.5M in Q3-2022 to approximately $1M in Q3-2023
NEW HAVEN, Conn., Oct. 03, 2023 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc.(NASDAQ: PRPO), announces that the combination of revenue growth and cost cutting initiatives has reduced Cash Burn From Operations (C... Full story
Yahoo Finance • last year
Precipio Continues to Sign New HemeScreen™ Customers
NEW HAVEN, Conn., Sept. 28, 2023 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) announced that new customer orders are expected to bring total Q4 HemeScreen revenues to an estimated $1.2M. In a re... Full story
Yahoo Finance • last year
Precipio Reduces Product Revenue Result Needed for Cash Flow Breakeven
NEW HAVEN, Conn., Sept. 25, 2023 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) announced that due to the increased pathology revenue, and the recent operational efficiencies, the company has reduc... Full story
Yahoo Finance • last year
Precipio’s Pathology Division Exceeds Breakeven Revenues in August, Four Months Ahead of Plan
NEW HAVEN, Conn., Sept. 13, 2023 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc.(NASDAQ: PRPO), announces its Pathology Division has in August exceeded the monthly breakeven revenue goal which, if continued, cause... Full story
Yahoo Finance • last year
Precipio Enters into Collaboration with Prestigious New York-based Institution to Develop Revolutionary Brain Tumor Panel using HemeScreen® Technology
NEW HAVEN, Conn., June 13, 2023 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), announces that it has entered into a collaboration agreement with a NY-based academic healthcare institution to joint... Full story
Yahoo Finance • 2 years ago
Precipio Shares Growth Catalysts For HemeScreen
NEW HAVEN, Conn., May 17, 2023 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), will be discussing on today’s shareholders call several growth catalysts that management has been tracking. The Compan... Full story
Yahoo Finance • 2 years ago
Precipio Announces Q1-2023 Shareholder Update Call
NEW HAVEN, Conn., May 15, 2023 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), will be hosting its Q1-2023 corporate update call on May 17th at 5:00 PM ET. The call will include updates on all of t... Full story
Yahoo Finance • 2 years ago
Precipio Adds Substantial Pathology Customer to its Diagnostic Services Division
NEW HAVEN, Conn., May 04, 2023 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) announces another agreement with a new pathology services customer to utilize Precipio’s diagnostic services. Based on... Full story
Yahoo Finance • 2 years ago
Precipio Signs Another HemeScreen™ Customer
NEW HAVEN, Conn., May 04, 2023 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) announces another agreement with a new customer to bring HemeScreen™ technology into their laboratory. With each additi... Full story
Yahoo Finance • 2 years ago
Precipio Granted 180-day Extension From NASDAQ To Regain Compliance
NEW HAVEN, Conn., April 27, 2023 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), announces notification by the NASDAQ Stock Market that the Company has been granted a 180-day extension to allow the... Full story
Yahoo Finance • 2 years ago
Precipio Unaudited Q1-2023 Product Revenues Exceed The Two Prior Quarters (Q3+Q4 of 2022) Combined
NEW HAVEN, Conn., April 19, 2023 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc.(NASDAQ: PRPO), announces that Q1-2023 product revenues have surpassed product revenues during the two prior quarters of 2022, and ex... Full story
Yahoo Finance • 2 years ago
Precipio Announces 2022 Fourth Quarter and Year-End Shareholder Update Call
NEW HAVEN, Conn., March 28, 2023 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), will be hosting its Q4-2022 and year end shareholder update call on Monday, April 3rd at 5:00 PM ET. The call will i... Full story
Yahoo Finance • 2 years ago
Precipio Ships First IV-Cell® Order to Major US Healthcare System
NEW HAVEN, Conn., March 21, 2023 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) delivered its first order of IV-Cell®, the Company’s proprietary cytogenetics cell culturing media, to a major US hea... Full story
Yahoo Finance • 2 years ago
Precipio continues to sign up and onboard HemeScreen™ customers
NEW HAVEN, Conn., March 07, 2023 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) continues to convert its sales pipeline into HemeScreen customers, with an additional recently signed agreement expec... Full story
Yahoo Finance • 2 years ago
Precipio Signs Another Major HemeScreen™ Customer
NEW HAVEN, Conn., Jan. 11, 2023 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) announced another 4-year agreement with a new customer to bring HemeScreen™ technology into their laboratory. Based o... Full story
Yahoo Finance • 2 years ago
Precipio Signs Additional Major HemeScreen™ Customer
NEW HAVEN, Conn., Dec. 06, 2022 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) announced a 4-year agreement with a new customer to bring HemeScreen™ technology into their lab. Based on volume info... Full story
Yahoo Finance • 2 years ago
Precipio Presents Poster on HemeScreen® Study at Association of Molecular Pathology (AMP) 2022 Annual Conference
NEW HAVEN, Conn., Nov. 07, 2022 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) presented at the annual 2022 AMP conference a poster presentation of the results of a groundbreaking study, conducted... Full story
Yahoo Finance • 2 years ago
Precipio Announces Third Quarter Shareholder Update Call
NEW HAVEN, Conn., Nov. 02, 2022 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), will be hosting its Q3-2022 shareholder update call on Monday, November 14th at 5:00 PM ET. The call will include upd... Full story
